Insuman Basal (Insuman Basal) 40IU/ML

$5.55

Each vial of Insuman Basal contains 40iu/ml of Insulin and comes in the 10 ml size vial and is used in treatment of Diabetes.

ATC Classification: A10AB01
Active Ingrediant: Human Insulin
Generic Name: Insuman Basal
Manufacturer: Sanofi Aventis GmbH Germany
Strength: 40IU/ML
Dosage Type: VIAL
Packaging Type: Box
Contains: 10 ML VIAL

Examples of Packages sent

Free worldwide shipping on all orders over $50

  • 30 days easy returns
  • Order yours before 2.30pm for same day dispatch
Guaranteed Safe Checkout

Placeholder
Insuman Basal (Insuman Basal) 40IU/ML
$5.55

[wpforms id=”1190″ title=”true” description=”Request a call back”]

Insuman Basal Information

Pronunciation

(IN soo lin N P H)

What is this drug used for?

• It is used to lower blood sugar in patients with high blood sugar (diabetes).

Frequently reported side effects of this drug

• Injection site irritation

• Weight gain

Other side effects of this drug: Talk with your doctor right away if you have any of these signs of:

• Low blood sugar like dizziness, headache, fatigue, feeling weak, shaking, fast heartbeat, confusion, increased hunger, or sweating.

• Low potassium like muscle pain or weakness, muscle cramps, or an abnormal heartbeat.

• Vision changes

• Burning or numbness feeling

• Severe dizziness

• Passing out

• Mood changes

• Seizures

• Slurred speech

• Swelling of arms or legs

• Injection site thick skin, pits, or lumps

• Signs of a significant reaction like wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat.

Medication Safety Issues

Sound-alike/look-alike issues:

HumuLIN N may be confused with HumuLIN R, HumaLOG, Humira

NovoLIN N may be confused with NovoLIN R, NovoLOG

High alert medication:

The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error. Due to the number of insulin preparations, it is essential to identify/clarify the type of insulin to be used.

Other safety concerns:

Cross-contamination may occur if insulin pens are shared among multiple patients. Steps should be taken to prohibit sharing of insulin pens.

Storage/Stability

Humulin N vials: Store unopened vials in refrigerator between 2°C and 8°C (36°F to 46°F; do not freeze; keep away from heat and sunlight. Once punctured (in use), vials may be stored for up to 31 days in the refrigerator between 2°C and 8°C (36°F to 46°F) or at room temperature ≤30°C (≤86°F)

Humulin N KwikPen: Store unopened in the refrigerator between 2°C and 8°C (36°F to 46°F); do not freeze; keep away from heat and sunlight. Once punctured (in use), should be stored below 30°C (86°F) for up to 14 days.

Novolin N vials: Store unopened vials in refrigerator between 2°C and 8°C (36°F to 46°F) until product expiration date or at room temperature ≤25°C (≤77°F) for up to 42 days; do not freeze; keep away from heat and sunlight. Once punctured (in use), store vials at room temperature ≤25°C (≤77°F) for up to 42 days; refrigeration of in-use vials is not recommended.

Novolin N FlexPen: Store unopened pen in the refrigerator between 2°C and 8°C (36°F to 46°F) until product expiration date or at room temperature <30°C (<86°F) for 28 days; do not freeze; keep away from heat and sunlight. Once punctured (in use), store <30°C (<86°F) for up to 28 days; refrigeration of in-use pens is not recommended.

Canadian products: Unopened vials, cartridges, and pens should be stored under refrigeration between 2°C and 8°C (36°F to 46°F) until the expiration date; do not freeze; keep away from heat and sunlight. Once punctured (in use), Humulin vials, cartridges and pens should be stored at room temperature <25°C (<77°F) for up to 4 weeks. Once punctured (in use), Novolin ge vials, cartridges, and pens may be stored for up to 1 month at room temperature <25°C (<77°F) for vials or <30°C (<86°F) for pens/cartridges; do not refrigerate.

Adverse Reactions

Frequency not defined.

Cardiovascular: Peripheral edema

Endocrine & metabolic: Hypoglycemia, hypokalemia, weight gain

Hypersensitivity: Hypersensitivity reaction

Immunologic: Immunogenicity

Local: Atrophy at injection site, hypertrophy at injection site, injection site reaction (including redness, swelling, and itching)

Neuromuscular & skeletal: Swelling of extremities

Ophthalmic: Visual disturbance

Additional information

Active Ingrediant

Generic Name

Alternate Names

, , , , , , , , , , , , , , , , , , , , , , , , , , ,

Strength

Dosage Type

Packaging Type